Developer docs
API playgroundTry for free, no card

Search company profiles

Lyotropic Delivery System

Full company profile

uuid002xxqo

Namestring
Lyotropic Delivery System
Legal namestring
LDS Biotech
Websiteurl
lds-biotech.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Lyotropic Delivery System (LDS Biotech) is a privately held Israeli nano-biotechnology company founded in 2013 and headquartered at the Edmond J. Safra Campus in Jerusalem. The company develops a proprietary liquid-structured nano-domain drug delivery platform — self-assembled, sub-100nm liquid lipid-based domains that solubilize active pharmaceutical and nutraceutical ingredients at the interface, rather than in the core, enabling higher loading, enhanced bioavailability, and controlled or triggered release. The platform relies on FDA Inactive Ingredient Guideline (IIG)-approved excipients and is supported by a proprietary Monte Carlo Dynamic Simulation mathematical model that maps bioactive chemical structure to optimal excipient composition across parameters such as spontaneous curvature, interfacial elasticity, and micro-viscosity. Application modules span oral, ophthalmic, topical/transdermal, parenteral, nasal, and thin-film delivery routes.

LDS monetizes primarily through B2B technology licensing and out-licensing agreements with pharmaceutical, nutraceutical, and cosmeceutical companies, generating royalties on products sold globally under partner brand names and milestone payments from long-term collaborative development arrangements. Customer-facing commercial products already on market include curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, vitamin D3, and phospholipid formulations. The clinical pipeline includes CBD-based products (Nantheia ATL5 series via Ananda Scientifics) being evaluated at multiple US academic medical centers across PTSD, opioid use disorder, chronic pain, social anxiety disorder, and smoking cessation indications, plus an ophthalmic cyclosporine product (Ocuvia / Operax) under an exclusive licensing option agreement via BioLight/OphRx. The company is led by founder Prof. Nissim Garti and holds 37+ granted patents globally with 40+ additional applications.

Short descriptiontext

Lyotropic Delivery System (LDS Biotech) is a privately held Jerusalem-based nano-biotechnology company that licenses proprietary sub-100nm liquid-structured nano-domain drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ophthalmic, topical, parenteral, nasal, and film routes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug delivery technology, nano-domain formulation, bioavailability enhancement, pharmaceutical excipients, technology licensing
Industry3 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Lessors of Nonfinancial Intangible Assets (except Copyrighted Works)533
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Miscellaneous Chemical Products2890
Product category
Drug Delivery Technology
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

LDS generates revenue through licensing its proprietary drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies. The company out-licenses its technology for specific active molecules, indications, and routes of administration. Revenue includes royalties from products sold globally under different brand names.

lds-biotech.com
2Collaborative Development
TypeLicensing Royalties
Description

Partnership and license agreements with companies like Ananda Scientifics for oral delivery of cannabinoids. Long-term R&D agreements for future generations of products generate development fees and milestone payments.

lds-biotech.com
3Nutraceutical Products
TypeLicensing Royalties
Description

Cosmeceutical and nutraceutical products already being sold globally under different brand names, yielding royalties to LDS. Products include curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, cannabinoids, vitamin D3, and phospholipids.

lds-biotech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Ocuvia™
Description

LDS-based ophthalmic drug delivery technology presented at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025.

lds-biotech.com
Core offering1 text field

LDS develops and out-licenses a proprietary liquid-structured nano-domain drug delivery platform that enhances the bioavailability, stability, and controlled release of insoluble and poorly permeable active molecules. It licenses this technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ocular, topical, parenteral, nasal, and film administration routes in exchange for royalties, milestones, and development fees.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 1A clinical trial for oral CBD uptake completed in 2020 demonstrating very fast CBD absorption (Tmax) and very high content of CBD active ingredient into the bloodstream
+3 more records
Product overview1 text field

LDS is a biotech company offering a proprietary Lyotropic Delivery System technology platform—a unified drug delivery solution utilizing molecularly engineered liquid-structured nano-domains. The platform serves as the core technology underlying multiple product applications: oral delivery (Nantheia ATL5 for cannabinoids), ophthalmic delivery (Ocuvia), topical/transdermal delivery, parenteral injection (NEOPROL/NP09), nasal delivery for BBB crossing, and film-based sustained release. The technology enhances bioavailability of insoluble and poorly permeable molecules using FDA-IIG-approved excipients. The company also commercializes nutraceutical products including curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, vitamin D3, and phosphatidylserine.

Product and service10 records
1LDS Lyotropic Delivery System Technology Platform
CategoryCore platform technology
Description

Proprietary drug delivery platform using liquid-structured nano-domains (<100nm) that enhances bioavailability and efficacy of insoluble and poorly permeable active molecules using FDA-IIG-approved excipients. Tailored for pharmaceutical, nutraceutical, and cosmeceutical companies across multiple administration routes.

2Oral Delivery System
CategoryApplication module
Description

Delivery technology that embeds generic or innovative bio-actives (APIs) to achieve enhanced bioavailability for oral uptake, protecting active molecules from harsh GI tract conditions. For pharmaceutical and nutraceutical companies.

3Ophthalmic Delivery System
CategoryApplication module
Description

Nano-sized domain delivery vehicles providing extensive interfacial contact with the eye epithelium, enabling enhanced permeation to anterior and posterior eye segments for water-insoluble molecules. For pharmaceutical companies developing ocular therapeutics.

4Topical and Transdermal Delivery System
CategoryApplication module
Description

Topical delivery systems with nano-liquid structures in soft gels or thin films enabling transport of insoluble active molecules to skin layers (epidermis/dermis) and nails, for skin disease treatment and transdermal absorption. For cosmeceutical and pharmaceutical companies.

5Parenteral Delivery System
CategoryApplication module
Description

Injectable formulations using nano-domains to encapsulate APIs, providing thermodynamic stability, reduced injection pain, improved solubility, decreased microbial contamination, and enhanced bioavailability. For pharmaceutical companies.

6Nasal Delivery System
CategoryApplication module
Description

Formulations designed for nasal applications for drug compounds that must cross the blood-brain barrier to reach the brain, enabling fast, quantitative, and accurate dosing. For pharmaceutical companies targeting CNS conditions.

7Film Delivery Technology
CategoryApplication module
Description

Multi-layer, self-adhesive, thin, transparent film technology that embeds nano-domains loaded with active molecules, providing sustained release for chronic disease treatments on nails, joints, and skin. For pharmaceutical and cosmeceutical companies.

8Nantheia ATL5
CategoryCBD-based product
Description

LDS-based oral CBD product developed in partnership with Ananda Scientific, featuring soft-gels, instant powders, and dilutable liquids for cannabinoid delivery; used in multiple clinical trials for OUD, PTSD, chronic pain, and anxiety indications.

9Ocuvia Ophthalmic Product
CategoryOphthalmic product
Description

Novel LDS-based ophthalmic drug delivery product (including cyclosporine formulation). Presented at the J.P. Morgan Healthcare Conference and subject of an exclusive licensing option agreement with a leading pharmaceutical company.

10NEOPROL Formulation (NP09)
CategoryInjectable product
Description

Parenteral (injectable) formulation demonstrating bio-equivalence to commercial products, validated in PK studies in dogs. For pharmaceutical companies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-22
Description

Clinical trial collaboration for smoking cessation using Nantheia ATL5 with LDS Liquid Structure CBD delivery technology. UCLA announced commencement of clinical trial evaluating LDS-based CBD formulation for smoking cessation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-15
Description

FDA-approved clinical trial for Nantheia ATL5 for opioid use disorder and chronic pain treatment using LDS Liquid Structure delivery technology. Yale is conducting clinical evaluation of LDS-based CBD delivery for these indications.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-09-19
Description

GHF showcased LDS novel delivery technology at the Adult Poly-Body Disease (APBD) Scientific & Community Conference for orphan indication treatment. GHF is developing treatments for orphan diseases using LDS technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-29
Description

BioLight subsidiary OphRx signed exclusive option for license agreement with leading pharmaceutical company for novel LDS-based ophthalmic technology. Positive clinical trial results achieved for cyclosporine ophthalmic formulation using LDS technology. Biolight operates in the Israeli market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-28
Description

Multiple clinical trial collaborations including first patient enrolled for Social Anxiety Disorder (SAD) treatment, PTSD trials, and opioid-sparing treatment in participants with radiculopathic pain using LDS Liquid Structure CBD delivery technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-17
Description

FDA approval of IND for clinical trial exploring PTSD treatment using LDS Liquid Structure CBD delivery technology. First patient enrolled March 2023.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-19
Description

Clinical evaluation of Liquid Structure CBD for opioid use disorder (OUD) using LDS Liquid Structure delivery technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

LDS entered into a partnership and license agreement with Ananda Scientifics (US-based company) for oral delivery of cannabinoids. Ananda Scientifics has signed a long-term R&D agreement with LDS for future generations of oral cannabinoid-based products in soft-gels, instant powders, and dilutable liquids. Technology is protected by patents issued in several countries and nutraceutical products are currently sold globally under different brand names yielding royalties to LDS. Multiple clinical trials ongoing including Phase 1A (completed 2020) and Phase 2a.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
TypeBroad incumbent
Description

Global CDMO offering API, peptide, and lipid-based drug product development including nano-formulations. Comparable as a contract manufacturer with overlapping lipid/delivery capabilities for pharma and nutraceutical customers.

TypeBroad incumbent
Description

Global specialty chemicals and excipient company serving pharmaceutical and personal care with drug delivery-enabling ingredients. Comparable as a much larger, established supplier of delivery-system components with broad portfolio reach.

TypeBroad incumbent
Description

German specialty chemicals and CDMO with pharmaceutical delivery solutions including lipid-based and polymeric systems. Comparable as a large, diversified player with overlapping lipid and nano-delivery capabilities.

TypeDirect peer
Description

US clinical-stage biopharmaceutical company focused on oral delivery of poorly soluble drugs using lipid-based technology. Directly comparable as a small lipid-delivery platform company commercializing through licensing and partnership arrangements.

TypeEmerging player
Description

US clinical-stage mRNA medicines company that developed its own lipid nanoparticle delivery platform (LUNAR) for nucleic acid therapeutics. Comparable as a smaller platform company with proprietary lipid-based delivery technology targeting licensing and partnership models.

TypeDirect peer
Description

Canadian lipid nanoparticle (LNP) delivery technology company that develops delivery systems for nucleic acid and small-molecule therapeutics. Most directly comparable to LDS in lipid-based nano-delivery platform technology and out-licensing business model.

TypeBroad incumbent
Description

US biopharmaceutical company that monetizes proprietary drug delivery and formulation platforms (e.g., Captisol) primarily through licensing and royalty agreements. Comparable platform-licensing business model applied to formulation technology.

TypeBroad incumbent
Description

German biotechnology company that pioneered lipid nanoparticle delivery for mRNA vaccines and therapeutics. Comparable for its foundational LNP delivery IP and licensing partnerships, though at vastly larger scale and focused on nucleic acid payloads.

10NanoCarrier
TypeDirect peer
Description

Japanese clinical-stage biotech developing micellar and polymeric nanoparticle drug delivery systems for oncology and other indications. Comparable as a smaller specialty nano-delivery platform targeting pharma partnership and licensing economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyotropic Delivery System

Drug Delivery Technologylds-biotech.com

Lyotropic Delivery System (LDS Biotech) is a privately held Jerusalem-based nano-biotechnology company that licenses proprietary sub-100nm liquid-structured nano-domain drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ophthalmic, topical, parenteral, nasal, and film routes.

What Lyotropic Delivery System does

Lyotropic Delivery System (LDS Biotech) is a privately held Israeli nano-biotechnology company founded in 2013 and headquartered at the Edmond J. Safra Campus in Jerusalem. The company develops a proprietary liquid-structured nano-domain drug delivery platform — self-assembled, sub-100nm liquid lipid-based domains that solubilize active pharmaceutical and nutraceutical ingredients at the interface, rather than in the core, enabling higher loading, enhanced bioavailability, and controlled or triggered release. The platform relies on FDA Inactive Ingredient Guideline (IIG)-approved excipients and is supported by a proprietary Monte Carlo Dynamic Simulation mathematical model that maps bioactive chemical structure to optimal excipient composition across parameters such as spontaneous curvature, interfacial elasticity, and micro-viscosity. Application modules span oral, ophthalmic, topical/transdermal, parenteral, nasal, and thin-film delivery routes.

LDS monetizes primarily through B2B technology licensing and out-licensing agreements with pharmaceutical, nutraceutical, and cosmeceutical companies, generating royalties on products sold globally under partner brand names and milestone payments from long-term collaborative development arrangements. Customer-facing commercial products already on market include curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, vitamin D3, and phospholipid formulations. The clinical pipeline includes CBD-based products (Nantheia ATL5 series via Ananda Scientifics) being evaluated at multiple US academic medical centers across PTSD, opioid use disorder, chronic pain, social anxiety disorder, and smoking cessation indications, plus an ophthalmic cyclosporine product (Ocuvia / Operax) under an exclusive licensing option agreement via BioLight/OphRx. The company is led by founder Prof. Nissim Garti and holds 37+ granted patents globally with 40+ additional applications.

Lyotropic Delivery System firmographics

Firmographics
Name
Lyotropic Delivery System
Legal name
LDS Biotech
Website
https://lds-biotech.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Lyotropic Delivery System (LDS Biotech) is a privately held Jerusalem-based nano-biotechnology company that licenses proprietary sub-100nm liquid-structured nano-domain drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ophthalmic, topical, parenteral, nasal, and film routes.
Ownership category
akta.pro rank

Lyotropic Delivery System industry classification

Industry
Product category
Drug Delivery Technology
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Drug delivery technology
  • Nano-domain formulation
  • Bioavailability enhancement
  • Pharmaceutical excipients
  • Technology licensing

Where Lyotropic Delivery System is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Lyotropic Delivery System business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Technology Licensing: LDS generates revenue through licensing its proprietary drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies. The company out-licenses its technology for specific active molecules, indications, and routes of administration. Revenue includes royalties from products sold globally under different brand names.
  2. Collaborative Development: Partnership and license agreements with companies like Ananda Scientifics for oral delivery of cannabinoids. Long-term R&D agreements for future generations of products generate development fees and milestone payments.
  3. Nutraceutical Products: Cosmeceutical and nutraceutical products already being sold globally under different brand names, yielding royalties to LDS. Products include curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, cannabinoids, vitamin D3, and phospholipids.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Lyotropic Delivery System product offering

Product offering

Core offering

LDS develops and out-licenses a proprietary liquid-structured nano-domain drug delivery platform that enhances the bioavailability, stability, and controlled release of insoluble and poorly permeable active molecules. It licenses this technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ocular, topical, parenteral, nasal, and film administration routes in exchange for royalties, milestones, and development fees.

Product overview

LDS is a biotech company offering a proprietary Lyotropic Delivery System technology platform—a unified drug delivery solution utilizing molecularly engineered liquid-structured nano-domains. The platform serves as the core technology underlying multiple product applications: oral delivery (Nantheia ATL5 for cannabinoids), ophthalmic delivery (Ocuvia), topical/transdermal delivery, parenteral injection (NEOPROL/NP09), nasal delivery for BBB crossing, and film-based sustained release. The technology enhances bioavailability of insoluble and poorly permeable molecules using FDA-IIG-approved excipients. The company also commercializes nutraceutical products including curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, vitamin D3, and phosphatidylserine.

Differentiator

Problem solved

Functional benefit

Brands

  • Ocuvia™: LDS-based ophthalmic drug delivery technology presented at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025.

Products and services

  • LDS Lyotropic Delivery System Technology Platform Proprietary drug delivery platform using liquid-structured nano-domains (<100nm) that enhances bioavailability and efficacy of insoluble and poorly permeable active molecules using FDA-IIG-approved excipients. Tailored for pharmaceutical, nutraceutical, and cosmeceutical companies across multiple administration routes.
  • Oral Delivery System Delivery technology that embeds generic or innovative bio-actives (APIs) to achieve enhanced bioavailability for oral uptake, protecting active molecules from harsh GI tract conditions. For pharmaceutical and nutraceutical companies.
  • Ophthalmic Delivery System Nano-sized domain delivery vehicles providing extensive interfacial contact with the eye epithelium, enabling enhanced permeation to anterior and posterior eye segments for water-insoluble molecules. For pharmaceutical companies developing ocular therapeutics.
  • Topical and Transdermal Delivery System Topical delivery systems with nano-liquid structures in soft gels or thin films enabling transport of insoluble active molecules to skin layers (epidermis/dermis) and nails, for skin disease treatment and transdermal absorption. For cosmeceutical and pharmaceutical companies.
  • Parenteral Delivery System Injectable formulations using nano-domains to encapsulate APIs, providing thermodynamic stability, reduced injection pain, improved solubility, decreased microbial contamination, and enhanced bioavailability. For pharmaceutical companies.
  • Nasal Delivery System Formulations designed for nasal applications for drug compounds that must cross the blood-brain barrier to reach the brain, enabling fast, quantitative, and accurate dosing. For pharmaceutical companies targeting CNS conditions.
  • Film Delivery Technology Multi-layer, self-adhesive, thin, transparent film technology that embeds nano-domains loaded with active molecules, providing sustained release for chronic disease treatments on nails, joints, and skin. For pharmaceutical and cosmeceutical companies.
  • Nantheia ATL5 LDS-based oral CBD product developed in partnership with Ananda Scientific, featuring soft-gels, instant powders, and dilutable liquids for cannabinoid delivery; used in multiple clinical trials for OUD, PTSD, chronic pain, and anxiety indications.
  • Ocuvia Ophthalmic Product Novel LDS-based ophthalmic drug delivery product (including cyclosporine formulation). Presented at the J.P. Morgan Healthcare Conference and subject of an exclusive licensing option agreement with a leading pharmaceutical company.
  • NEOPROL Formulation (NP09) Parenteral (injectable) formulation demonstrating bio-equivalence to commercial products, validated in PK studies in dogs. For pharmaceutical companies.

Quantifiable outcome

  • Phase 1A clinical trial for oral CBD uptake completed in 2020 demonstrating very fast CBD absorption (Tmax) and very high content of CBD active ingredient into the bloodstream
  • +3 more outcomes

Companies that use Lyotropic Delivery System

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Lyotropic Delivery System technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Lyotropic Delivery System partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • UCLA David Geffen School of MedicinecoreStrategic or Co-development Partner · 22 October 2024Clinical trial collaboration for smoking cessation using Nantheia ATL5 with LDS Liquid Structure CBD delivery technology. UCLA announced commencement of clinical trial evaluating LDS-based CBD formulation for smoking cessation.
  • Yale School of MedicinecoreStrategic or Co-development Partner · 15 October 2024FDA-approved clinical trial for Nantheia ATL5 for opioid use disorder and chronic pain treatment using LDS Liquid Structure delivery technology. Yale is conducting clinical evaluation of LDS-based CBD delivery for these indications.
  • Golden Heart Flower (GHF)minorStrategic or Co-development Partner · 19 September 2024GHF showcased LDS novel delivery technology at the Adult Poly-Body Disease (APBD) Scientific & Community Conference for orphan indication treatment. GHF is developing treatments for orphan diseases using LDS technology.
  • BioLight Life Sciences / OphRxcoreStrategic or Co-development Partner · 29 February 2024BioLight subsidiary OphRx signed exclusive option for license agreement with leading pharmaceutical company for novel LDS-based ophthalmic technology. Positive clinical trial results achieved for cyclosporine ophthalmic formulation using LDS technology. Biolight operates in the Israeli market.
  • NYU Grossman School of MedicinecoreStrategic or Co-development Partner · 28 March 2023Multiple clinical trial collaborations including first patient enrolled for Social Anxiety Disorder (SAD) treatment, PTSD trials, and opioid-sparing treatment in participants with radiculopathic pain using LDS Liquid Structure CBD delivery technology.
  • University of Nebraska Medical CentercoreStrategic or Co-development Partner · 17 May 2022FDA approval of IND for clinical trial exploring PTSD treatment using LDS Liquid Structure CBD delivery technology. First patient enrolled March 2023.
  • Mount Sinai Icahn School of MedicinecoreStrategic or Co-development Partner · 19 October 2021Clinical evaluation of Liquid Structure CBD for opioid use disorder (OUD) using LDS Liquid Structure delivery technology.
  • Ananda ScientificscoreStrategic or Co-development Partner · 1 January 2015LDS entered into a partnership and license agreement with Ananda Scientifics (US-based company) for oral delivery of cannabinoids. Ananda Scientifics has signed a long-term R&D agreement with LDS for future generations of oral cannabinoid-based products in soft-gels, instant powders, and dilutable liquids. Technology is protected by patents issued in several countries and nutraceutical products are currently sold globally under different brand names yielding royalties to LDS. Multiple clinical trials ongoing including Phase 1A (completed 2020) and Phase 2a.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Lyotropic Delivery System competitors and assessment

Company assessment

Others

Broad incumbents

  • CordenPharma: Global CDMO offering API, peptide, and lipid-based drug product development including nano-formulations. Comparable as a contract manufacturer with overlapping lipid/delivery capabilities for pharma and nutraceutical customers.
  • Croda International: Global specialty chemicals and excipient company serving pharmaceutical and personal care with drug delivery-enabling ingredients. Comparable as a much larger, established supplier of delivery-system components with broad portfolio reach.
  • Evonik Industries: German specialty chemicals and CDMO with pharmaceutical delivery solutions including lipid-based and polymeric systems. Comparable as a large, diversified player with overlapping lipid and nano-delivery capabilities.
  • Ligand Pharmaceuticals: US biopharmaceutical company that monetizes proprietary drug delivery and formulation platforms (e.g., Captisol) primarily through licensing and royalty agreements. Comparable platform-licensing business model applied to formulation technology.
  • BioNTech: German biotechnology company that pioneered lipid nanoparticle delivery for mRNA vaccines and therapeutics. Comparable for its foundational LNP delivery IP and licensing partnerships, though at vastly larger scale and focused on nucleic acid payloads.

Direct peers

  • Lipocine: US clinical-stage biopharmaceutical company focused on oral delivery of poorly soluble drugs using lipid-based technology. Directly comparable as a small lipid-delivery platform company commercializing through licensing and partnership arrangements.
  • Acuitas Therapeutics: Canadian lipid nanoparticle (LNP) delivery technology company that develops delivery systems for nucleic acid and small-molecule therapeutics. Most directly comparable to LDS in lipid-based nano-delivery platform technology and out-licensing business model.
  • NanoCarrier: Japanese clinical-stage biotech developing micellar and polymeric nanoparticle drug delivery systems for oncology and other indications. Comparable as a smaller specialty nano-delivery platform targeting pharma partnership and licensing economics.

Emerging players

  • Arcturus Therapeutics: US clinical-stage mRNA medicines company that developed its own lipid nanoparticle delivery platform (LUNAR) for nucleic acid therapeutics. Comparable as a smaller platform company with proprietary lipid-based delivery technology targeting licensing and partnership models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Lyotropic Delivery System social profiles

Digital presence

Lyotropic Delivery System compliance and trust

Trust signal

Compliance1 record

Lyotropic Delivery System financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyotropic Delivery System leadership team

Management profile

Number of profiles

Profiles1 record

Lyotropic Delivery System subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Lyotropic Delivery System funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyotropic Delivery System M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyotropic Delivery System

What does Lyotropic Delivery System do?

LDS develops and out-licenses a proprietary liquid-structured nano-domain drug delivery platform that enhances the bioavailability, stability, and controlled release of insoluble and poorly permeable active molecules. It licenses this technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ocular, topical, parenteral, nasal, and film administration routes in exchange for royalties, milestones, and development fees.

Is Lyotropic Delivery System a public or private company?

Lyotropic Delivery System is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lyotropic Delivery System founded?

Lyotropic Delivery System was founded in 2013. It employs 1 to 10 people.

Where is Lyotropic Delivery System based?

Lyotropic Delivery System is headquartered in Jerusalem, Israel, in the Middle East region.

How does Lyotropic Delivery System make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are collaborative Development and nutraceutical Products.

Who are Lyotropic Delivery System's main competitors?

Catalent is listed as an others. Broad incumbents are CordenPharma, Croda International, Evonik Industries, Ligand Pharmaceuticals and BioNTech. Direct peers are Lipocine, Acuitas Therapeutics and NanoCarrier. Arcturus Therapeutics is listed as an emerging player.

Does Lyotropic Delivery System have an API?

No public API is recorded for Lyotropic Delivery System.

What industry is Lyotropic Delivery System in?

Lyotropic Delivery System's product category is Drug Delivery Technology. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals